In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems

WCK 5222 (cefepime-zidebactam, 2 g + 1g, every 8 h [q8h]) is in clinical development for the treatment of infections caused by carbapenem-resistant and multidrug-resistant (MDR) Gram-negative bacilli. We determined the in vitro susceptibility of 1,385 clinical isolates of non-carbapenem-susceptible...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrob Agents Chemother
Main Authors: Karlowsky, James A., Hackel, Meredith A., Bouchillon, Samuel K., Sahm, Daniel F.
Format: Artigo
Language:Inglês
Published: American Society for Microbiology 2020
Subjects:
Susceptibility
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7674044/
https://ncbi.nlm.nih.gov/pubmed/32928739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01432-20
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items